DK2155874T3 - FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone - Google Patents

FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone Download PDF

Info

Publication number
DK2155874T3
DK2155874T3 DK08742686.2T DK08742686T DK2155874T3 DK 2155874 T3 DK2155874 T3 DK 2155874T3 DK 08742686 T DK08742686 T DK 08742686T DK 2155874 T3 DK2155874 T3 DK 2155874T3
Authority
DK
Denmark
Prior art keywords
pth
lys
collagen
ser
bone
Prior art date
Application number
DK08742686.2T
Other languages
Danish (da)
English (en)
Inventor
Joshua Sakon
Osamu Matsushita
Tulasi Ponnapakkam
Robert C Gensure
Original Assignee
Univ Arkansas
Nat Univ Corp Kagawa Univ
Ochsner Clinic Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Nat Univ Corp Kagawa Univ, Ochsner Clinic Found filed Critical Univ Arkansas
Application granted granted Critical
Publication of DK2155874T3 publication Critical patent/DK2155874T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
DK08742686.2T 2007-04-09 2008-04-09 FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone DK2155874T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92243307P 2007-04-09 2007-04-09
PCT/US2008/004589 WO2008124166A2 (en) 2007-04-09 2008-04-09 Fusion proteins of collagen-binding domain and parathyroid hormone

Publications (1)

Publication Number Publication Date
DK2155874T3 true DK2155874T3 (en) 2016-08-01

Family

ID=39831527

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08742686.2T DK2155874T3 (en) 2007-04-09 2008-04-09 FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone
DK16169069.8T DK3091075T3 (en) 2007-04-09 2008-04-09 FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYRO OIDA HORMON

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16169069.8T DK3091075T3 (en) 2007-04-09 2008-04-09 FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYRO OIDA HORMON

Country Status (7)

Country Link
US (6) US8450273B2 (OSRAM)
EP (2) EP2155874B1 (OSRAM)
JP (4) JP5520811B2 (OSRAM)
CA (2) CA2683862C (OSRAM)
DK (2) DK2155874T3 (OSRAM)
ES (2) ES2583002T3 (OSRAM)
WO (1) WO2008124166A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2155874T3 (en) * 2007-04-09 2016-08-01 Univ Arkansas FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone
US20110294192A1 (en) * 2008-11-19 2011-12-01 Tohoku University Fusion collagenase in which affinity tag is linked and method for producing the same
EP2405008A1 (en) * 2010-07-06 2012-01-11 LanthioPep B.V. Bacterial surface display of thioether-bridge-containing peptides
US9173919B2 (en) 2011-02-16 2015-11-03 Purdue Research Foundation Collagen-targeted nanoparticles
JP5512887B2 (ja) * 2011-05-13 2014-06-04 学校法人北里研究所 成長因子アンカーリング型骨移植材料および成長因子アンカーリング型骨移植材料製造用キット
ES2816009T3 (es) * 2011-12-14 2021-03-31 Univ Arkansas Administración de agentes terapéuticos mediante una proteína de unión a colágeno
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
US8969290B2 (en) 2012-06-26 2015-03-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
WO2016085280A1 (ko) 2014-11-28 2016-06-02 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US11213613B2 (en) 2015-06-12 2022-01-04 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Three-dimensional tissue scaffold with stem cell attracting element and use thereof
BR112018017091A2 (pt) 2016-03-01 2019-01-02 Ascendis Pharma Bone Diseases As profármacos de pth
CN109789189B (zh) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
NZ751745A (en) 2016-09-29 2023-05-26 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
ES3012647T3 (en) 2016-09-29 2025-04-09 Ascendis Pharma Bone Diseases As Controlled-release pth compounds
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2018148573A1 (en) * 2017-02-10 2018-08-16 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
CN107213517B (zh) * 2017-05-17 2020-03-27 宁波大学 一种复合骨水泥及其制备方法
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
KR101964376B1 (ko) * 2017-09-29 2019-04-01 주식회사 나이벡 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
KR102891411B1 (ko) 2019-02-11 2025-11-25 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
WO2021030196A1 (en) * 2019-08-09 2021-02-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
WO1994022468A1 (en) 1993-04-02 1994-10-13 Anticancer, Inc. Method for delivering beneficial compositions to hair follicles
US5925552A (en) 1996-04-25 1999-07-20 Medtronic, Inc. Method for attachment of biomolecules to medical devices surfaces
WO1998004591A1 (en) 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
US6428579B1 (en) 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6387663B1 (en) * 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
EP1151116A1 (en) 1999-02-19 2001-11-07 Terumo Kabushiki Kaisha Collagen-binding physiologically active polypeptide
JP2001190280A (ja) * 1999-02-19 2001-07-17 Terumo Corp コラーゲン結合性生理活性ポリペプチド
US20020102709A1 (en) * 1999-02-19 2002-08-01 Tetsuya Ishikawa Collagen-binding physiologically active polypeptide
US6908994B1 (en) * 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20040053368A1 (en) * 2000-08-15 2004-03-18 Tetsuya Ishikawa Collagen-binding hybrid polypeptide
JP2002058485A (ja) 2000-08-16 2002-02-26 Terumo Corp コラーゲン結合性を有する骨形成促進融合蛋白質
US20020063621A1 (en) 2000-09-01 2002-05-30 Next Planet, Inc. Method and apparatus for device communications
US6812217B2 (en) 2000-12-04 2004-11-02 Medtronic, Inc. Medical device and methods of use
JP4560291B2 (ja) 2001-12-18 2010-10-13 イジュノシッヒ テクニッヒ ホッフシューラ チューリッヒ 組織操作のための成長因子改変タンパク質マトリクス
JP4750416B2 (ja) * 2002-07-25 2011-08-17 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン受容体の活性化と造血前駆細胞の増殖
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
ES2269973T3 (es) 2003-02-13 2007-04-01 Synthes Ag Chur Mezcla inyectable para sustituir un tejido oseo.
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
EP1680073B1 (en) 2003-10-21 2013-01-02 IGF Oncology, LLC Compounds and method for treating cancer
WO2005046798A1 (en) * 2003-11-12 2005-05-26 Nps Allelix Corp. Treatment of bone loss utilizing full length parathyroid hormone
EP1557176A1 (en) 2004-01-26 2005-07-27 Ferring B.V. Treatment of bone metastases by means of PTH receptor agonists
US20090005298A1 (en) 2004-02-27 2009-01-01 The University Of Western Ontario Bone Sialoprotein Collagen-Binding Peptides
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
EP1812082B1 (en) 2004-10-21 2013-08-14 IGF Oncology, LLC Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
ATE514712T1 (de) 2005-12-26 2011-07-15 Yantai Zhenghai Bio Technology Co Ltd Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren
DK2155874T3 (en) * 2007-04-09 2016-08-01 Univ Arkansas FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone
JP2010172247A (ja) 2009-01-29 2010-08-12 Kitasato Institute 積層型高密度培養人工組織の製造方法及び積層型高密度培養人工組織
JPWO2011142425A1 (ja) 2010-05-12 2013-07-22 国立大学法人 香川大学 上皮層含有組織の再生材および再生評価方法
JP5512887B2 (ja) 2011-05-13 2014-06-04 学校法人北里研究所 成長因子アンカーリング型骨移植材料および成長因子アンカーリング型骨移植材料製造用キット
ES2816009T3 (es) 2011-12-14 2021-03-31 Univ Arkansas Administración de agentes terapéuticos mediante una proteína de unión a colágeno
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein

Also Published As

Publication number Publication date
US20130337017A1 (en) 2013-12-19
WO2008124166A8 (en) 2009-11-05
DK3091075T3 (en) 2018-07-16
CA2683862C (en) 2016-08-02
EP2155874B1 (en) 2016-05-11
WO2008124166A2 (en) 2008-10-16
US8450273B2 (en) 2013-05-28
US10202434B2 (en) 2019-02-12
JP5821066B2 (ja) 2015-11-24
EP2155874A4 (en) 2010-09-01
US9528099B2 (en) 2016-12-27
US20170101457A1 (en) 2017-04-13
ES2583002T3 (es) 2016-09-16
EP3091075B1 (en) 2018-06-13
US20190338010A1 (en) 2019-11-07
US10519213B2 (en) 2019-12-31
US20150284701A1 (en) 2015-10-08
JP5989876B2 (ja) 2016-09-07
EP2155874A2 (en) 2010-02-24
JP2014040431A (ja) 2014-03-06
CA2930681A1 (en) 2008-10-16
WO2008124166A3 (en) 2009-01-15
JP6366653B2 (ja) 2018-08-01
US10358471B2 (en) 2019-07-23
EP3091075A1 (en) 2016-11-09
JP2017025069A (ja) 2017-02-02
US9062300B2 (en) 2015-06-23
CA2930681C (en) 2019-10-15
ES2675174T3 (es) 2018-07-09
US20100129341A1 (en) 2010-05-27
JP5520811B2 (ja) 2014-06-11
US20190135890A1 (en) 2019-05-09
JP2016094385A (ja) 2016-05-26
CA2683862A1 (en) 2008-10-16
JP2010523671A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
DK2155874T3 (en) FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone
JP6916918B2 (ja) 骨形成を促進するための組成物および方法
JP6025002B2 (ja) 骨形成または血管新生促進用ペプチドｂｆｐ４およびその用途
JP2004536056A (ja) Ｒａｎｋアンタゴニストの療法使用
EP2766384B1 (en) Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
KR101637497B1 (ko) 골형성 펩타이드 및 이의 용도
JP2002058485A (ja) コラーゲン結合性を有する骨形成促進融合蛋白質
JP2005512509A5 (OSRAM)
JP2005508157A5 (OSRAM)
US11208468B2 (en) Methods and compositions for treating melanoma
AU2002257303A1 (en) Therapeutic use of rank antagonists